Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Capital Expenditures: 2011-2025

Historic Capital Expenditures for Vanda Pharmaceuticals (VNDA) over the last 13 years, with Sep 2025 value amounting to $161,000.

  • Vanda Pharmaceuticals' Capital Expenditures changed negligibly% to $161,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year increase of 109.83%. This contributed to the annual value of $490,000 for FY2024, which is 27.94% up from last year.
  • According to the latest figures from Q3 2025, Vanda Pharmaceuticals' Capital Expenditures is $161,000, which was down 46.15% from $299,000 recorded in Q2 2025.
  • In the past 5 years, Vanda Pharmaceuticals' Capital Expenditures ranged from a high of $436,000 in Q1 2025 and a low of -$10,000 during Q3 2021.
  • Over the past 3 years, Vanda Pharmaceuticals' median Capital Expenditures value was $161,000 (recorded in 2025), while the average stood at $160,818.
  • In the last 5 years, Vanda Pharmaceuticals' Capital Expenditures crashed by 104.07% in 2021 and then spiked by 6,128.57% in 2025.
  • Vanda Pharmaceuticals' Capital Expenditures (Quarterly) stood at $134,000 in 2021, then skyrocketed by 96.27% to $263,000 in 2022, then fell by 3.80% to $253,000 in 2023, then declined by 15.42% to $214,000 in 2024, then remained steady at $161,000 in 2025.
  • Its Capital Expenditures was $161,000 in Q3 2025, compared to $299,000 in Q2 2025 and $436,000 in Q1 2025.